Screening for Prostate Cancer in Black Men

While the incidence of prostate cancer has declined in general over the years, the incidence and mortality rate among black men is disproportionately high. Screening recommendations differ among medical organizations, perpetuating the divide; this article aims to raise awareness and deliver clear direction for screening.

Sandra Meria Keavey, DHSc, DFAAPA, PA-C; Walter Jermaine Thompson, DHSc, MPH, CHES

Prostate cancer, the second most common cancer to affect American men, is a slow-growing cancer that is curable when detected early. While the overall incidence has declined in the past 20 years (see Figure 1), prostate cancer remains a major concern among black men due to disproportionate incidence and mortality rates.1-3 A general understanding of the prostate and of prostate cancer lays the groundwork to acknowledge and address this divide.

ANATOMY OF THE PROSTATE

Although most men know where the prostate gland is located, many do not understand how it functions.4 The largest ac-
cessory gland of the male reproductive system, the prostate is located below the bladder and in front of the rectum (see Figure 2). The urethra passes through this gland; therefore, enlargement of the prostate can cause constriction of the urethra, which can affect the ability to eliminate urine from the body.

The prostate is broken down into four distinct regions (see Figure 3, next page). Certain types of inflammation may occur more often in some regions of the prostate than others; as such, 75% of prostate cancer occurs in the peripheral zone (the region located closest to the rectal wall).

**DIAGNOSING PROSTATE CANCER**

**Signs and symptoms**

According to the CDC, the signs and symptoms of prostate cancer include

- Difficulty starting urination
- Weak or interrupted flow of urine
- Frequent urination (especially at night)
- Difficulty emptying the bladder
- Pain or burning during urination
- Blood in the urine or semen
- Pain in the back, hips, or pelvis
- Painful ejaculation.

However, none of these signs and symptoms are unique to prostate cancer. For instance, difficulty starting urination, weak or interrupted flow of urine, and frequent urination can also be attributed to benign prostatic hyperplasia. Further, in its early stages, prostate cancer may not exhibit any signs or symptoms, making accurate screening essential for detection and treatment.

**Screening tools**

There are two primary tools for detection of prostate cancer: the prostate-specific antigen (PSA) test and the digital rectal exam (DRE). The blood test for PSA is routinely used as a screening tool and is therefore considered a standard test for prostate cancer. A PSA level above 4.0 ng/mL is considered abnormal. Although measuring the PSA level can improve the odds of early prostate cancer detection, there is considerable debate over its dependability in this regard, as PSA can be elevated for benign reasons.

**Sociocultural and genetic risk factors**

While both black and white men are at an increased risk for prostate cancer if a first-degree relative (ie, father, brother, son) had the disease, one in five black men will develop prostate cancer in their lifetimes, compared with one in seven white men. And despite a five-year survival rate of nearly 100% for regional prostate cancer, black men are more than two times as likely as...
white men to die of the disease (1 in 23 and 1 in 38, respectively).8,11 From 2011 to 2015, the age-adjusted mortality rate of prostate cancer among black men was 40.8, versus 18.2 for non-Hispanic white men (per 100,000 population).12

The disparity in prostate cancer mortality among black men has been attributed to multiple variables. Cultural differences can play a role in whether patients choose to undergo prostate cancer screening. Black men are, for example, less likely than other men to participate in preventive health care practices.13 Although an in-depth discussion is outside the scope of this article, researchers have identified some plausible factors for this, including economic limitations, lack of access to health care, distrust of the health care system, and an indifference to pain or discomfort.13,14 Decisions surrounding prostate screening can also be affected by a patient’s perceived risk for prostate cancer, the impact of a cancer diagnosis, and the availability of treatment.

Other factors that contribute to the higher incidence and mortality rate among black men include genetic predisposition, health beliefs, and knowledge about the prostate and cancer screenings.15 While most researchers have focused on men ages 40 and older, Ogunsanya et al suggested that educating black men about screening for prostate cancer at an earlier age may help them to make informed decisions later in life.15

IMPLICATIONS FOR PRACTICE

The age at which men should begin screening for prostate cancer has been a source of controversy due to the lack of consensus between the American Cancer Society, the American Urological Association, and the United States Preventive Services Task Force (USPSTF) guidelines (see Table).16-18 The current USPSTF recommendations for prostate cancer screening do not take into account ethnic differences, despite the identified racial disparity.19 Ambiguity in public health policy creates a quandary in the decision-making process regarding testing and treatment.9,19,20

Early screening and intervention is necessary to help mitigate prostate cancer morbidity and mortality.21 The authors support the use of the American Cancer Society guidelines, which are comprehensive and clearly define who is considered to be at risk. The guidelines suggest screening black men and men with known family histories (considered to be at high risk) at age 45, and screening men with a strong family history (multiple first-degree relatives who developed prostate cancer at a young age) beginning at age 40.

In addition, these guidelines recommend the use of both the DRE and PSA screening tests. Screening should be performed every two years for men who have a PSA level < 2.5 ng/mL, and every year for men who have a level > 2.5 ng/mL.
TREATMENT

Fortunately, there are several treatment options for men who are diagnosed with prostate cancer. These include watchful waiting, surgery, radiation, cryotherapy, hormone therapy, and chemotherapy. The type of treatment chosen depends on many factors, such as the tumor grade or cancer stage, the implications for quality of life, and the shared provider/patient decision-making process. Indeed, choosing the right treatment is a specialized approach that varies according to case and circumstance.

CONCLUSION

There has been an increase in prostate cancer screening in recent years. However, black men still lag behind when it comes to having DRE and PSA tests. Many factors, including cultural perceptions of medical care among black men, often cause delays in seeking evaluation and treatment. Developing consistent and uniform prostate cancer screening recommendations for black men would be an important step in reducing mortality and morbidity in this population.

REFERENCES

The radiograph demonstrates an abnormal-appearing patella; there is a longitudinal lucency along the lateral portion. There is some mild soft-tissue swelling but no evidence of a definite joint effusion.

The lucency could represent a fracture, especially in the setting of trauma. The other possibility is that the patient has a bipartite patella. This is a rare congenital condition in which the patella does not completely fuse; it remains two separate bones.

CT of the knee for further evaluation, as well as orthopedic consultation, were ordered.

ANSWER

The radiograph demonstrates an abnormal-appearing patella; there is a longitudinal lucency along the lateral portion. There is some mild soft-tissue swelling but no evidence of a definite joint effusion.

The lucency could represent a fracture, especially in the setting of trauma. The other possibility is that the patient has a bipartite patella. This is a rare congenital condition in which the patella does not completely fuse; it remains two separate bones.

CT of the knee for further evaluation, as well as orthopedic consultation, were ordered.

ANSWER

The radiograph demonstrates an abnormal-appearing patella; there is a longitudinal lucency along the lateral portion. There is some mild soft-tissue swelling but no evidence of a definite joint effusion.

The lucency could represent a fracture, especially in the setting of trauma. The other possibility is that the patient has a bipartite patella. This is a rare congenital condition in which the patella does not completely fuse; it remains two separate bones.

CT of the knee for further evaluation, as well as orthopedic consultation, were ordered.